We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Name | Symbol | Market | Type |
---|---|---|---|
Nokia Corp | NYSE:NOK | NYSE | Depository Receipt |
Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
0.045 | 1.22% | 3.735 | 3.74 | 3.72 | 3.725 | 860,996 | 14:56:23 |
By Ben Glickman
MiMedx Group said on Friday it received an FDA warning letter related to the classification of its product Axiofill. The regulator has reaffirmed that the company's treatment doesn't qualify as a Section 361 product, meaning it likely requires pre-market review. Shares fall 6.5% to $8.20 after-hours.
Nokia expects to miss its 2023 financial outlook as license-renewal discussions stretch into 2024. The company expects to miss guidance on net sales, comparable operating margin and free cash flow, and can't provide preliminary financial results for the quarter because the reporting period hasn't concluded. Shares fall 1.5% to $3.37 after-hours.
Write to Ben Glickman at ben.glickman@wsj.com
(END) Dow Jones Newswires
December 29, 2023 18:24 ET (23:24 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Nokia Chart |
1 Month Nokia Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions